Gunnar Brinkmalm

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/937056/gunnar-brinkmalm-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106 60 3,840 34 h-index g-index citations papers 4,831 6.3 111 5.12 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
106	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry <i>EBioMedicine</i> , 2022 , 75, 103793	8.8	O
105	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103846	4	
104	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility <i>Nature Reviews Neurology</i> , 2022 ,	15	4
103	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021 , 13, e15098	12	4
102	Characterization of monomeric and soluble aggregated Alin Down's syndrome and Alzheimer's disease brains. <i>Neuroscience Letters</i> , 2021 , 754, 135894	3.3	5
101	Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2021 , 18, 23	7	3
100	Plasma ACE2 species are differentially altered in COVID-19 patients. <i>FASEB Journal</i> , 2021 , 35, e21745	0.9	7
99	Refining the amyloid [peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. <i>Journal of Neurochemistry</i> , 2021 , 159, 234-257	6	0
98	Molecular forms of neurogranin in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2021 , 157, 816-833	6	3
97	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer</i> and Dementia, 2021 , 17, 755-767	1.2	31
96	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimerps Disease</i> , 2021 , 79, 729-741	4.3	4
95	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. <i>Clinica Chimica Acta</i> , 2021 , 512, 74-83	6.2	4
94	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. <i>Alzheimerp</i> s and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021 , 13, e12179	5.2	4
93	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021 , 141, 709-724	14.3	83
92	Amyloid pathology and synaptic loss in pathological aging. <i>Journal of Neurochemistry</i> , 2021 , 159, 258-23	726	O
91	Execretase modulators show selectivity for Execretase-mediated amyloid precursor protein intramembrane processing <i>Journal of Cellular and Molecular Medicine</i> , 2021 ,	5.6	2
90	Characterization of monomeric and soluble aggregated Alin Down syndrome and Alzheimer disease brains. <i>Alzheimer and Dementia</i> , 2020 , 16, e042479	1.2	

(2019-2020)

89	Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. Journal of Alzheimerps Disease, 2020 , 74, 1143-1156	4.3	4
88	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2020 ,	15.1	30
87	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020 , 134, 104645	7.5	12
86	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020 , 143, 650-660	11.2	33
85	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. <i>Scientific Reports</i> , 2020 , 10, 18075	4.9	8
84	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology, The</i> , 2020 , 19, 422-433	24.1	286
83	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimerps Research and Therapy</i> , 2019 , 11, 82	9	26
82	Identification of neurotoxic cross-linked amyloid-Idimers in the Alzheimer's brain. <i>Brain</i> , 2019 , 142, 144	1-114-57	40
81	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. <i>PLoS ONE</i> , 2019 , 14, e0212815	3.7	4
80	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019 , 9, 5522	4.9	12
79	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. <i>Neuroscience Letters</i> , 2019 , 701, 125-131	3.3	25
78	Pyroglutamation of amyloid-🛭 -42 (A և -42) followed by A 🗗 -40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <i>Journal of Biological Chemistry</i> , 2019 , 294, 6719-6732	5.4	30
77	P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO EAMYLOID POSITIVITY 2019 , 15, P1517-P1519		
76	P4-519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID 2019 , 15, P1513-P1513		
75	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019 , 124, 428-438	7.5	7
74	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 279-296	14.3	79
73	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019 , 151, 417-434	6	10
72	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 89-102	14.3	47

71	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <i>Proteomics - Clinical Applications</i> , 2018 , 12, 1700131	3.1	62
70	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 62	7.3	3
69	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimerps Research and Therapy</i> , 2018 , 10, 5	9	63
68	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018 , 12, 799-812	2.3	39
67	P1-217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE 2018 , 14, P361-P362		
66	Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. <i>Molecular Neurodegeneration</i> , 2018 , 13, 47	19	18
65	Expanding the cerebrospinal fluid endopeptidome. <i>Proteomics</i> , 2017 , 17, 1600384	4.8	23
64	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017 , 11, 1700100	3.1	19
63	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. <i>Expert Review of Proteomics</i> , 2017 , 14, 1007-1020	4.2	16
62	Low-dose Becretase inhibition increases secretion of Alpeptides and intracellular oligomeric All <i>Molecular and Cellular Neurosciences</i> , 2017 , 85, 211-219	4.8	5
61	[P3Ø84]: N-TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH IN-HOUSE CLEAVAGE-SPECIFIC ANTIBODY 2017 , 13, P964-P964		
60	[P1fl87]: NOVEL METHOD FOR OLIGOMERIC AIDETECTION REVEALS INTRACELLULAR ACCUMULATION OF AIDPON LOW-DOSE TREATMENT WITH A GAMMA-SECRETASE INHIBITOR 2017 , 13, P314-P314		
59	[P1Ø68]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY 2017 , 13, P352-P352		
58	[P2🛮58]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION 2017 , 13, P668-P668		
57	[P2Ø46]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES 2017 , 13, P706-P707		
56	[P4B92]: NOVEL ASSAYS TO MONITOR AIPEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE 2017 , 13, P1478		
55	[P4월70]: PRESYNAPTIC DEGRADATION IN ALZHEIMER'S DISEASE MEASURED BY NOVEL GAP-43 ELISA IN CSF 2017 , 13, P1513		
54	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	1

(2012-2016)

53	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016 , 13, 4	5	18
52	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimerps Research and Therapy</i> , 2016 , 8, 41	9	78
51	Heteromers of amyloid precursor protein in cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , 2015 , 10, 2	19	22
50	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer</i> and Dementia, 2015 , 11, 1180-90	1.2	201
49	The aqueous phase of Alzheimer's disease brain contains assemblies built from ~4 and ~7 kDa All species. <i>Alzheimerp</i> and <i>Dementia</i> , 2015 , 11, 1286-305	1.2	41
48	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <i>Alzheimerps Research and Therapy</i> , 2015 , 7, 40	9	90
47	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015 , 1854, 769-78	4	36
46	Targeting synaptic pathology with a novel affinity mass spectrometry approach. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 2584-92	7.6	22
45	Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides. <i>Journal of Proteome Research</i> , 2014 , 13, 6024-32	5.6	100
44	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014 , 9, 53	19	150
43	Synthesis aided structural determination of amyloid-[11-15] glycopeptides, new biomarkers for Alzheimer's disease. <i>Chemical Communications</i> , 2014 , 50, 15067-70	5.8	11
42	The amyloid-degradation pattern in plasmaa possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014 , 573, 7-12	3.3	48
41	Soluble amyloid precursor protein and In CSF in Alzheimer's disease. <i>Brain Research</i> , 2013 , 1513, 117-2	63.7	38
40	CSF Presenilin-1 complexes are increased in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 46	7.3	16
39	Cerebrospinal fluid biomarkers of Emyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 543-52	5	37
38	Mass spectrometric characterization of amyloid-Ispecies in the 7PA2 cell model of Alzheimer's disease. <i>Journal of Alzheimer</i> Disease, 2013 , 33, 85-93	4.3	44
37	Amyloid-Imetabolism in Niemann-Pick C disease models and patients. <i>Metabolic Brain Disease</i> , 2012 , 27, 573-85	3.9	35
36	An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603	2.2	64

35	BACE1 inhibition induces a specific cerebrospinal fluid hmyloid pattern that identifies drug effects in the central nervous system. <i>PLoS ONE</i> , 2012 , 7, e31084	3.7	60
34	SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. <i>Journal of Proteomics</i> , 2011 , 75, 425-34	3.9	45
33	A novel pathway for amyloid precursor protein processing. <i>Neurobiology of Aging</i> , 2011 , 32, 1090-8	5.6	116
32	Identification of novel Bynuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <i>Neurochemical Research</i> , 2011 , 36, 2029-42	4.6	74
31	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 11848-53	11.5	165
30	Proteomics profiling of single organs from individual adult zebrafish. Zebrafish, 2010 , 7, 161-8	2	23
29	Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. <i>Experimental Neurology</i> , 2010 , 223, 351-8	5.7	33
28	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010 , 120, 185-93	14.3	226
27	Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. <i>Neurodegenerative Diseases</i> , 2009 , 6, 87-94	2.3	59
26	Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2009 , 6, 258-62	2.3	25
25	Enrichment of glycopeptides for glycan structure and attachment site identification. <i>Nature Methods</i> , 2009 , 6, 809-11	21.6	264
24	The Applicability of Enzymes in Cellulose Ether Analysis. <i>Macromolecular Symposia</i> , 2009 , 280, 36-44	0.8	3
23	Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 1793-806	2.8	20
22	A Mass Spectrometer's Building Blocks 2008 , 15-87		4
21	Definitions and Explanations 2008 , 3-13		
20	Characterization of tau in cerebrospinal fluid using mass spectrometry. <i>Journal of Proteome Research</i> , 2008 , 7, 2114-20	5.6	62
19	Separation Methods 2008 , 105-115		
18	Tandem Mass Spectrometry 2008 , 89-103		1

LIST OF PUBLICATIONS

17	Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. <i>Journal of Proteome Research</i> , 2007 , 6, 4433-9	5.6	113
16	Comprehensive analysis of the substituent distribution in hydroxyethyl celluloses by quantitative MALDI-ToF-MS. <i>Macromolecular Bioscience</i> , 2006 , 6, 435-44	5.5	16
15	Substituent distribution and clouding behavior of hydroxypropyl methyl cellulose analyzed using enzymatic degradation. <i>Biomacromolecules</i> , 2006 , 7, 3474-81	6.9	19
14	Characterization of chemical substitution of hydroxypropyl cellulose using enzymatic degradation. <i>Biomacromolecules</i> , 2006 , 7, 80-5	6.9	24
13	New approaches to the analysis of enzymatically hydrolyzed methyl cellulose. Part 2. Comparison of various enzyme preparations. <i>Biomacromolecules</i> , 2006 , 7, 1410-21	6.9	19
12	New approaches to the analysis of enzymatically hydrolyzed methyl cellulose. Part 1. Investigation of the influence of structural parameters on the extent of degradation. <i>Biomacromolecules</i> , 2006 , 7, 13	99:409	19
11	An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. <i>Neuroscience Letters</i> , 2006 , 409, 215-9	3.3	101
10	Improved chemical analysis of cellulose ethers using dialkylamine derivatization and mass spectrometry. <i>Biomacromolecules</i> , 2005 , 6, 2793-9	6.9	9
9	Derivatization using dimethylamine for tandem mass spectrometric structure analysis of enzymatically and acidically depolymerized methyl cellulose. <i>Analytical Chemistry</i> , 2005 , 77, 2948-59	7.8	25
8	Improved matrix-assisted laser desorption/ionisation sample preparation of a partially depolymerised cellulose derivative by continuous spray deposition and interfacing with size-exclusion chromatography. <i>Rapid Communications in Mass Spectrometry</i> , 2005 , 19, 947-54	2.2	7
7	Development of a size exclusion chromatography method for the determination of molar mass for poloxamers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003 , 31, 845-58	3.5	7
6	Sample preparation effects in matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of partially depolymerised carboxymethyl cellulose. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 1107-15	2.2	25
5	Sample preparation effects in matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of partially depolymerised methyl cellulose. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 1116-24	2.2	14
4	Analytical approaches to improved characterization of substitution in hydroxypropyl cellulose. <i>Analytical Chemistry</i> , 2003 , 75, 6077-83	7.8	21
3	Enzyme-aided investigation of the substituent distribution in cationic potato amylopectin starch. <i>Analytical Chemistry</i> , 2003 , 75, 6499-508	7.8	24
2	Enzymatic degradation of carboxymethyl cellulose hydrolyzed by the endoglucanases Cel5A, Cel7B, and Cel45A from Humicola insolens and Cel7B, Cel12A and Cel45Acore from Trichoderma reesei. <i>Biopolymers</i> , 2002 , 63, 32-40	2.2	70
1	Formation of fullerenes in MeV ion track plasmas. <i>Chemical Physics Letters</i> , 1992 , 191, 345-350	2.5	38